March 26, 2020
ZPREDICTA, LABCORP PARTNER ON 3D CELL CULTURE TECHNOLOGY
The collaboration supports the adoption of zPredicta’s 3D cell culture platform for preclinical testing and research studies.
February 27, 2020
ZPREDICTA, LABCORP FORM CANCER CELL CULTURE MODEL PARTNERSHIP
NEW YORK — zPredicta said on Thursday that it has partnered with Laboratory Corporation of America to develop and commercialize tumor-specific preclinical models based on its 3D cell culture platform. zPredicta’s platform integrates organ-specific cellular and extracellular elements into 3D culture models for in vitro cancer drug testing.
February 27, 2020
ZPREDICTA ENTERS STRATEGIC COLLABORATION WITH LABCORP TO ADVANCE THE USE OF 3D CELL CULTURES IN RESEARCH AND DRUG DEVELOPMENT
SAN JOSE, Calif.–(BUSINESS WIRE)–zPREDICTA, Inc., the leading provider of tumor-specific 3D cell culture models for the in vitro testing of anti-cancer therapeutics, is pleased to announce that it has entered into a strategic collaboration with LabCorp, a leading global life sciences company. The agreement will support the adoption of zPREDICTA’s proprietary 3D cell culture platform for preclinical testing and research studies in the biopharmaceutical industry.
November 5, 2018
ZPREDICTA COLLABORATES WITH SCIENCE EXCHANGE TO OFFER UNIQUE PATIENT-DERIVED CELL CULTURE SERVICES TO DRUG DEVELOPMENT RESEARCHERS
PALO ALTO, Calif.–(BUSINESS WIRE)–Science Exchange, the world’s leading marketplace for outsourced R&D, has announced that it is working with zPREDICTA to offer online access to its predictive cancer drug development and testing services.
November 30, 2017
2017 WORLD ALLIANCE FORUM: HEALTHCARE GAME CHANGERS
Panel Discussion: Successful Drug Discovery & Development…Increasing the Odds
REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies
August 4, 2017
TAKING THE GUESSWORK OUT OF DRUG DEVELOPMENT
California-based company zPREDICTA™ has created a novel technology that reconstructs physiologically-relevant organ-specific human microenvironments that help eliminate the guesswork from drug development. Meaningful drug discovery studies involve complex experiments that are not feasible to perform manually. Automation is the answer, improving accuracy, saving time and reducing the amount of compound used.
March 7, 2017
RECONSTRUCTING CANCER TREATMENT: ZPREDICTA DEAL PROFILE
Imagine if each and every cancer patient got a custom treatment based on their bodies’ makeup, which in turn increased the likelihood of the treatment’s success?
June 6, 2016
ZPREDICTA ANNOUNCES REVOLUTIONARY CANCER DRUG TESTING PLATFORM
zPREDICTA today announces the immediate availability of its Reconstructed Bone Marrow (r-Bone™) platform, providing a radical shift in drug testing approach since the 1950s.
July 23, 2015
METASTASIS IN 3D: HOW IXCHEL’S (ZPREDICTA) 3D TISSUE MODEL MIMICS METASTASIS FOR SCREENING CANCER THERAPIES
Current in vivo and in vitro models for testing cancer therapeutics don’t accurately model the progression of metastasis, which limits their ability to predict efficacy in patients. Ixchel’s (zPREDICTA) PD-3D system is a cell-based 3D model that mimics the spread of cancer in human tissues, and aims to predict the clinical success of cancer therapies more reliably than other models.
July 23, 2015
IXCHEL SCIENTIFIC (NOW ZPREDICTA) (YC S15) CAN PREDICT HOW THE HUMAN BODY WILL REACT TO CANCER DRUGS
Ixchel Scientific, a startup launching out of our current class, is making a tool that aims to more accurately predict how cancer drugs will behave in the body by creating organ-specific testing environments.
July 21, 2015
Y COMBINATOR-BACKED IXCHEL (NOW ZPREDICTA) PREDICTS HOW CANCER DRUGS WILL BEHAVE IN HUMANS BEFORE YOU EVEN SWALLOW A PILL
Biotech startup Ixchel Scientific (now zPREDICTA) hopes to bring higher success rates to trialed cancer drugs using an environment that better represents the human body.
September 1, 2014
EDITORIAL: THE INNOVATIVE MEDICINES INITIATIVE – COLLABORATIONS ARE KEY TO INNOVATING R&D PROCESSES